AR038648A1 - Hormona paratiroidea en forma cristalina y proceso para purificar la hormona paratiroidea y obtener dicha forma cristalina - Google Patents

Hormona paratiroidea en forma cristalina y proceso para purificar la hormona paratiroidea y obtener dicha forma cristalina

Info

Publication number
AR038648A1
AR038648A1 ARP980106420A ARP980106420A AR038648A1 AR 038648 A1 AR038648 A1 AR 038648A1 AR P980106420 A ARP980106420 A AR P980106420A AR P980106420 A ARP980106420 A AR P980106420A AR 038648 A1 AR038648 A1 AR 038648A1
Authority
AR
Argentina
Prior art keywords
pth
crystal form
solution
hormone
concentration
Prior art date
Application number
ARP980106420A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of AR038648A1 publication Critical patent/AR038648A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/635—Parathyroid hormone (parathormone); Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders

Abstract

Reivindicación (1): Una hormona paratiroidea en forma cristalina caracterizada porque se selecciona del grupo que consiste de PTH (1-34), PTH (1-37), PTH (1-38) y PTH (1-41). Reivindicación (6): Un proceso para purificar y obtener la hormona paratiroidea en forma cristalina de acuerdo con la reivindicación (1), caracterizada porque comprende: a) proporcionar una solución acuosa de una hormona paratiroidea seleccionada del grupo que consiste de PTH (1-34), PTH (1-37), PTH (1-38) y PTH (1-41) a una concentración de 5 a alrededor de 40 mg por ml; b) mezclar dicha solución con solución de reserva que comprende un solvente orgánico en una concentración de alrededor de 5 a alrededor de 50 volumen por ciento de un amortiguador en una concentración para mantener el pH de la solución entre alrededor de 6.0 a alrededor 12.0; y c) permitir que la solución resultante pare a un tiempo determinado a una temperatura entre alrededor de la temperatura ambiente y alrededor de 4°C hasta que se forme los cristales tipo placa.
ARP980106420A 1997-12-18 1998-12-16 Hormona paratiroidea en forma cristalina y proceso para purificar la hormona paratiroidea y obtener dicha forma cristalina AR038648A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6987597P 1997-12-18 1997-12-18

Publications (1)

Publication Number Publication Date
AR038648A1 true AR038648A1 (es) 2005-01-26

Family

ID=22091750

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980106420A AR038648A1 (es) 1997-12-18 1998-12-16 Hormona paratiroidea en forma cristalina y proceso para purificar la hormona paratiroidea y obtener dicha forma cristalina

Country Status (24)

Country Link
US (1) US6590081B1 (es)
EP (1) EP0926158B1 (es)
JP (1) JP2002508395A (es)
KR (1) KR20010033268A (es)
CN (1) CN1281467A (es)
AR (1) AR038648A1 (es)
AT (1) ATE245165T1 (es)
AU (1) AU748271B2 (es)
BR (1) BR9813740A (es)
CA (1) CA2315103A1 (es)
DE (1) DE69816409T2 (es)
DK (1) DK0926158T3 (es)
EA (1) EA200000672A1 (es)
ES (1) ES2202729T3 (es)
HU (1) HUP0100075A2 (es)
ID (1) ID25660A (es)
IL (1) IL136824A0 (es)
NO (1) NO20003131D0 (es)
PE (1) PE20000056A1 (es)
PL (1) PL341209A1 (es)
PT (1) PT926158E (es)
TR (1) TR200002179T2 (es)
WO (1) WO1999031137A1 (es)
ZA (1) ZA9811407B (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7601685B2 (en) 1998-08-27 2009-10-13 Eidgenossische Technische Hochschule Zurich Growth factor modified protein matrices for tissue engineering
MXPA04006021A (es) * 2001-12-18 2005-08-19 Eth Zuerich Matrices de proteina modificada con factor de crecimiento para ingenieria de tejidos.
US7247609B2 (en) 2001-12-18 2007-07-24 Universitat Zurich Growth factor modified protein matrices for tissue engineering
EP1864681A1 (en) 2001-12-18 2007-12-12 Eidgenössische Technische Hochschule Zürich Growth factor modified protein matrices for tissue engineering
AU2003278766A1 (en) * 2002-09-04 2004-03-29 Microchips, Inc. Method and device for the controlled delivery of parathyroid hormone
SG176314A1 (en) 2002-12-31 2011-12-29 Altus Pharmaceuticals Inc Human growth hormone crystals and methods for preparing them
US8088734B2 (en) 2003-01-21 2012-01-03 Unigene Laboratories Inc. Oral delivery of peptides
US7553827B2 (en) * 2003-08-13 2009-06-30 Depuy Spine, Inc. Transdiscal administration of cycline compounds
US8273347B2 (en) 2003-05-13 2012-09-25 Depuy Spine, Inc. Autologous treatment of degenerated disc with cells
US7344716B2 (en) * 2003-05-13 2008-03-18 Depuy Spine, Inc. Transdiscal administration of specific inhibitors of pro-inflammatory cytokines
US20040229878A1 (en) * 2003-05-13 2004-11-18 Depuy Spine, Inc. Transdiscal administration of specific inhibitors of P38 kinase
US7429378B2 (en) * 2003-05-13 2008-09-30 Depuy Spine, Inc. Transdiscal administration of high affinity anti-MMP inhibitors
US8361467B2 (en) * 2003-07-30 2013-01-29 Depuy Spine, Inc. Trans-capsular administration of high specificity cytokine inhibitors into orthopedic joints
US8895540B2 (en) 2003-11-26 2014-11-25 DePuy Synthes Products, LLC Local intraosseous administration of bone forming agents and anti-resorptive agents, and devices therefor
US20060052305A1 (en) * 2004-05-10 2006-03-09 Nastech Pharmaceutical Company Inc. Method of treating osteoporosis using intranasal parathyroid hormone
AU2005247369A1 (en) * 2004-05-10 2005-12-08 Mdrna, Inc. Compositions and methods for enhanced mucosal delivery of parathyroid hormone
US20060127320A1 (en) * 2004-05-10 2006-06-15 Nastech Pharmaceutical Company Inc. Method of delivering parathyroid hormone to a human
WO2005112984A2 (en) 2004-05-13 2005-12-01 Alza Corporation Apparatus and method for transdermal delivery of parathyroid hormone agents
US8575101B2 (en) 2005-01-06 2013-11-05 Kuros Biosurgery Ag Supplemented matrices for the repair of bone fractures
WO2006073711A2 (en) 2005-01-06 2006-07-13 Kuros Biosurgery Ag Use of a matrix comprising a contrast agent in soft tissues
US7691105B2 (en) 2005-09-26 2010-04-06 Depuy Spine, Inc. Tissue augmentation, stabilization and regeneration technique
US20070088436A1 (en) 2005-09-29 2007-04-19 Matthew Parsons Methods and devices for stenting or tamping a fractured vertebral body
US20070173447A1 (en) * 2005-10-25 2007-07-26 Nastech Pharmaceutical Company Inc. Method for treating osteoporosis by intranasal delivery of teriparatide with an anti-resorptive agent
EP1945245A2 (en) * 2005-11-10 2008-07-23 The Board of Control of Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
US20080051332A1 (en) * 2005-11-18 2008-02-28 Nastech Pharmaceutical Company Inc. Method of modulating hematopoietic stem cells and treating hematologic diseases using intranasal parathyroid hormone
US20070168041A1 (en) * 2006-01-17 2007-07-19 Sudhakar Kadiyala Method and instruments for intervertebral disc augmentation through a pedicular approach
MX2009011005A (es) 2007-04-13 2009-11-02 Kuros Biosurgery Ag Sellador polimerico para tejido.
CA2694562A1 (en) * 2007-08-09 2009-02-12 Usv Limited Novel orthogonal process for purification of recombinant human parathyroid hormone (rhpth) (1-34)
US8741329B2 (en) * 2007-09-21 2014-06-03 Merck Sharp & Dohme B.V. Drug delivery system
US8241363B2 (en) 2007-12-19 2012-08-14 Depuy Spine, Inc. Expandable corpectomy spinal fusion cage
US8241294B2 (en) 2007-12-19 2012-08-14 Depuy Spine, Inc. Instruments for expandable corpectomy spinal fusion cage
US20090162351A1 (en) * 2007-12-21 2009-06-25 Depuy Spine, Inc. Transdiscal administration of inhibitors of p38 MAP kinase
US8986696B2 (en) * 2007-12-21 2015-03-24 Depuy Mitek, Inc. Trans-capsular administration of p38 map kinase inhibitors into orthopedic joints
JP2012512812A (ja) 2007-12-28 2012-06-07 クロス・バイオサージェリー・アクチェンゲゼルシャフト フィブリンフォームに組込まれたｐｄｇｆ融合タンパク質
US8876905B2 (en) 2009-04-29 2014-11-04 DePuy Synthes Products, LLC Minimally invasive corpectomy cage and instrument
AU2009356227A1 (en) 2009-12-07 2012-06-21 Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
US8865220B2 (en) 2010-06-14 2014-10-21 Kaohsiung Medical University Method for controlled release of parathyroid hormone from encapsulated poly(lactic-glycolic)acid microspheres
ES2882852T3 (es) 2011-03-16 2021-12-02 Kuros Biosurgery Ag Formulación farmacéutica para la utilización en la fusión espinal
CN102731643A (zh) * 2012-06-26 2012-10-17 深圳翰宇药业股份有限公司 一种治疗骨质疏松多肽的制备方法
US10413504B2 (en) 2013-12-11 2019-09-17 Merck Sharp & Dohme Corp. Intravaginal ring drug delivery system
EP3079659B1 (en) 2013-12-11 2020-10-28 Merck Sharp & Dohme B.V. Drug delivery system for delivery of anti-virals
CN104910269B (zh) * 2015-06-02 2018-08-17 成都圣诺生物科技股份有限公司 一种合成特立帕肽的方法
EP3685849A4 (en) * 2017-09-22 2021-12-22 Asahi Kasei Pharma Corporation LIQUID PHARMACEUTICAL COMPOSITION CONTAINING TRIPARATIDE WITH EXCELLENT STABILITY

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62106000A (ja) * 1985-10-30 1987-05-16 Fujitsu Ltd 生体高分子結晶自動作製装置
JP2802084B2 (ja) * 1987-10-20 1998-09-21 ホリック，マイケル・エフ ペプチドを用いた細胞の増殖と分化の調節
AU2764492A (en) * 1991-10-09 1993-05-03 Schering Corporation Crystal forming device and automated crystallization system
US5400741A (en) 1993-05-21 1995-03-28 Medical Foundation Of Buffalo, Inc. Device for growing crystals
US5496801A (en) * 1993-12-23 1996-03-05 Allelix Biopharmaceuticals Inc. Parathyroid hormone formulation
US5419278A (en) 1994-05-25 1995-05-30 Carter; Daniel C. Vapor equilibration tray for growing protein crystals
CA2178894A1 (en) * 1995-06-15 1996-12-16 Tsunehiko Fukuda Parathyroid hormone derivatives and their use

Also Published As

Publication number Publication date
PE20000056A1 (es) 2000-02-08
DK0926158T3 (da) 2003-11-10
DE69816409T2 (de) 2004-06-09
EP0926158A1 (en) 1999-06-30
AU748271B2 (en) 2002-05-30
JP2002508395A (ja) 2002-03-19
BR9813740A (pt) 2000-10-10
CA2315103A1 (en) 1999-06-24
AU1632699A (en) 1999-07-05
TR200002179T2 (tr) 2001-07-23
ZA9811407B (en) 2000-07-13
US6590081B1 (en) 2003-07-08
IL136824A0 (en) 2001-06-14
NO20003131L (no) 2000-06-16
DE69816409D1 (de) 2003-08-21
NO20003131D0 (no) 2000-06-16
PL341209A1 (en) 2001-03-26
ATE245165T1 (de) 2003-08-15
EA200000672A1 (ru) 2000-12-25
ES2202729T3 (es) 2004-04-01
KR20010033268A (ko) 2001-04-25
PT926158E (pt) 2003-11-28
ID25660A (id) 2000-10-19
EP0926158B1 (en) 2003-07-16
HUP0100075A2 (hu) 2001-05-28
CN1281467A (zh) 2001-01-24
WO1999031137A1 (en) 1999-06-24

Similar Documents

Publication Publication Date Title
AR038648A1 (es) Hormona paratiroidea en forma cristalina y proceso para purificar la hormona paratiroidea y obtener dicha forma cristalina
AR010224A1 (es) Metodo para preparar sales de litio
AR016197A1 (es) Nuevas formas de preparados galenicas de meloxicam para la aplicacion oral
CO5560540A2 (es) Composicion cristalina que contiene escitalopram
AR077412A2 (es) Formulacion farmaceutica composicon farmaceutica acuosa y formulacion farmaceutica acuosa liquida que comprende un anticuerpo
ES2060360T3 (es) Metodo para la cristalizacion de enzimas.
AR240876A2 (es) Un procedimiento para la preparacion de un catalizador que contiene plata y dicho catalizador
BR8802654A (pt) Processo de extracao e de purificacao de galio contido em uma solucao industrial de aluminato de sodio
DK90683D0 (da) Fremgangsmade til udvinding af insulin fra et insulin-protaminkompleks
BRPI0400375B8 (pt) processo para remover vírus em soluções de fibrinogênio para aplicação terapêutica
AR048279A1 (es) La forma ii cristalina de cabergolina
UY23842A1 (es) Proceso termoquimico de limpieza de tanques de almacenamiento
MX168598B (es) Metodo de membrana enzimatica para la sintesis y separacion de peptidos.
PE20060720A1 (es) Procedimiento para fabricar r-(-)-sertaconazol mononitrato
CO5320611A1 (es) Una composicion para extraer sales metalicas divalentes, un metodo para prepararla y su uso para reducir los depositos de sales metalicas divalentes en un sistema acuoso
MX169230B (es) Sistema adhesivo de separadores laminados para celdas electroquimicas
DK0801028T3 (da) Fremgangsmåde til selektiv genvinding af saltkomponenterne fra nitrit-nitrat-holdige hærderiaffaldssalte
EP0331745A4 (en) Ferrocene derivatives, surfactants containing same, and process for producing thin organic film
BR9917116A (pt) Método de preparação de pantotenato de cálcio
AR036018A1 (es) Proceso para aislar monohidrato de imipenem cristalino puro
PE20030920A1 (es) Formas cristalinas de agonistas del receptor b3-adrenergico, procedimiento para su preparacion y sus usos
AR012060A1 (es) UN PROCESO PARA LA PURIFICACIoN DE UN COMPUESTO DERIVADO DE P-NITRO FENOXI FENIL.
MX172582B (es) Mejoras en un procedimiento para separar bario respecto de sales de estroncio solubles en agua
ES2184948T3 (es) Capsulas que contienen diclofenaco o sus sales en forma de solucion.
JPS5362358A (en) Method of purifying waste water from desulfurization of exhaust gas

Legal Events

Date Code Title Description
FB Suspension of granting procedure